Alliance Pharma PLC Changes to interests of a significant shareholder (9489I)
June 22 2017 - 12:22PM
UK Regulatory
TIDMAPH
RNS Number : 9489I
Alliance Pharma PLC
22 June 2017
For immediate release 22 June 2017
ALLIANCE PHARMA PLC
("Alliance" or the "Company")
Changes to interests of a significant shareholder
Alliance Pharma plc (AIM: APH), the speciality pharmaceutical
company, has received a notification of a change in the interests
of a significant shareholder. In accordance with AIM rule 17, the
following details are now notified:
(a) Identity of the significant shareholder: GVQ Investment
Management Limited
(b) Date of disclosure: 22 June 2017
(c) Date of relevant change: 21 June 2017
(d) Price, amount and class: 1,000,000 ordinary shares of 1p
each; price not disclosed
(e) Nature of transaction: sale of shares
(f) Nature and extent of significant shareholder's interest: direct and indirect interests
(g) Resultant shareholding: 23,950,000 shares, with a direct
interest in the shares and an indirect interest in the voting
rights, in each case amounting to 5.05%
In compliance with DTR5, a copy of the notification received
from this investor is appended.
For further information:
Alliance Pharma plc + 44 (0) 1249 466966
John Dawson, Chief Executive
Andrew Franklin, Chief Financial
Officer
Rob Bellhouse, Company Secretary
www.alliancepharma.co.uk
+ 44 (0) 20 7466
Buchanan 5000
Mark Court / Sophie Cowles
+ 44 (0) 20 7260
Numis Securities Limited 1000
Nominated Adviser: Michael
Meade / Freddie Barnfield
Corporate Broking: James
Black / Toby Adcock
Notes to editors:
About Alliance Pharma
Alliance, founded in 1998, is an international speciality
pharmaceutical company based in Chippenham, Wiltshire, UK. The
Company has sales in more than 100 countries worldwide via direct
sales, joint ventures and a network of distributors. Alliance has a
strong track record of acquiring the rights to established niche
products and it currently owns or licenses the rights to
approximately 90 pharmaceutical and consumer healthcare products.
The Company continues to explore opportunities to expand its
product portfolio.
Alliance joined the AIM market of the London Stock Exchange in
December 2003 and trades under the symbol APH.
TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES
--------------------------------------------------------------------------------------
1. Identity of the issuer or Alliance Pharma
the underlying issuer
of existing shares to which
voting rights are
attached:
---------------------------------------------------------- --------------------------
2 Reason for the notification (please tick the appropriate
box or boxes):
--------------------------------------------------------------------------------------
An acquisition or disposal of voting rights X
---------------------------------------------------------- --------------------------
An acquisition or disposal of qualifying financial
instruments which may result in the acquisition
of shares already issued to which voting rights
are attached
---------------------------------------------------------- --------------------------
An acquisition or disposal of instruments with
similar economic effect to qualifying financial
instruments
---------------------------------------------------------- --------------------------
An event changing the breakdown of voting rights
---------------------------------------------------------- --------------------------
Other (please specify):
---------------------------------------------------------- --------------------------
3. Full name of person(s) GVQ Investment Management
subject to the Ltd
notification obligation:
---------------------------------------------------------- --------------------------
4. Full name of shareholder(s) Nortrust Nominees Ltd
(if different from 3.):
---------------------------------------------------------- --------------------------
5. Date of the transaction 21/06/2017
and date on
which the threshold is
crossed or
reached:
---------------------------------------------------------- --------------------------
6. Date on which issuer 22/06/2017
notified:
---------------------------------------------------------- --------------------------
7. Threshold(s) that is/are
crossed or
reached: 5%
---------------------------------------------------------- --------------------------
8. Notified details:
----------------------------------------------------------------------------------------------------------------------
A: Voting rights attached to shares
----------------------------------------------------------------------------------------------------------------------
Class/type Situation previous Resulting situation after the
of to the triggering triggering transaction
shares transaction
if possible
using
the ISIN
CODE
------------- ---------------------------------- -------------------------------------------------------------------
Number Number Number Number of % of voting
of of of shares voting rights
Shares Voting rights
Rights
------------- ---------------- ---------------- -------------- ------------------------ -------------------------
Direct Direct Indirect Direct Indirect
------------- ------------ ------------ -------------- --------- ------------- ------------ -----------
GB0031030819 22,950,000 22,950,000 23,950,000 0 23,950,000 0 5.05%
---------------- ---------------- -------------- --------- ------------- ------------ -----------
B: Qualifying Financial Instruments
----------------------------------------------------------------------------------------------------------------------
Resulting situation after the triggering transaction
----------------------------------------------------------------------------------------------------------------------
Type of Expiration Exercise/ Number of voting % of voting
financial date Conversion rights that rights
instrument Period may be
acquired if
the
instrument
is
exercised/
converted.
----------------- -------------- -------------------------------- -------------------------- ---------------------
C: Financial Instruments with similar economic effect
to Qualifying Financial Instruments
----------------------------------------------------------------------------------------------------------------------
Resulting situation after the triggering transaction
----------------------------------------------------------------------------------------------------------------------
Type of Exercise Expiration Exercise/ Number of voting % of voting
financial price date Conversion rights instrument rights
instrument (xvii) period refers to
(xviii)
--------------- -------------- -------------- ---------------- -------------------------- -----------------------
Nominal Delta
--------------- -------------- -------------- ---------------- -------------------------- ------------ ---------
Total (A+B+C)
----------------------------------------------------------------------------------------------------------------------
Number of voting rights Percentage of voting rights
--------------------------------------------------- -----------------------------------------------------------------
23,950,000 5.05%
--------------------------------------------------- -----------------------------------------------------------------
9. Chain of controlled undertakings through which the
voting rights and/or the
financial instruments are effectively held, if applicable:
-----------------------------------------------------------------------------
Proxy Voting:
-----------------------------------------------------------------------------
10. Name of the proxy holder:
------------------------------------------------------------- --------------
11. Number of voting rights proxy
holder will cease
to hold:
------------------------------------------------------------- --------------
12. Date on which proxy holder will
cease to hold
voting rights:
------------------------------------------------------------- --------------
13. Additional information:
------------------------------------------------------------- --------------
14. Contact name: Rahul Kunder
------------------------------------------------------------- --------------
15. Contact telephone number: 020 3824 4506
------------------------------------------------------------- --------------
This information is provided by RNS
The company news service from the London Stock Exchange
END
HOLPGUGPQUPMGQP
(END) Dow Jones Newswires
June 22, 2017 12:22 ET (16:22 GMT)
Alliance Pharma (LSE:APH)
Historical Stock Chart
From Feb 2024 to Mar 2024
Alliance Pharma (LSE:APH)
Historical Stock Chart
From Mar 2023 to Mar 2024